Investment thesis · BayesPharma GenRx
The operating system for generic drug development.
Turn fragmented reference-product, formulation, dissolution, BE/PBPK, CMC, quality and regulatory evidence into one governed path toward ANDA readiness.
Scientific boundary: GenRx is evidence-governed digital decision infrastructure. It does not replace accountable scientific, quality or regulatory review, and it does not claim regulatory authority.
Why now
Six forces are converging on the same operational problem.
Generic-development teams are being asked to move faster while keeping scientific and regulatory reasoning traceable. The opportunity is not another isolated calculator. It is the programme layer connecting the work.
Patent-expiry pressure
More programmes compete on timing, prioritisation and execution discipline.
Complex generics
Harder products create more dependencies across formulation, analytics, BE, CMC and regulatory strategy.
Model-informed development
PBPK, dissolution, PK and simulation can matter where scientifically appropriate - but only when context and assumptions remain inspectable.
Margin compression
Generic economics make avoidable experimental cycles, duplicated analysis and decision latency especially expensive.
Evidence complexity
ANDA development requires evidence continuity across functions, versions and review cycles.
Scientific AI
AI becomes useful when every claim can be separated into retrieved, predicted, computed, measured and human-reviewed evidence.
Structural problem
Generic programmes move data. They often lose context.
A development decision may depend on reference-product evidence, formulation rationale, analytical methods, BE assumptions, scale-up constraints and regulatory interpretation - but those objects often live in different systems.
Today: fragmented work
RLD intelligence
Formulation files
Analytical systems
BE / PK modelling
CMC + quality
Regulatory authoring
Data moves. Context, assumptions and review history are repeatedly reconstructed.
With GenRx: one programme state
Evidence - source + version + applicability
Methods - model + assumptions + context
Decisions - rationale + uncertainty + owner
Reviews - status + sign-off + audit trail
Readiness - gaps + next actions + dependencies
Portfolio - reusable governed learning
Evidence -> methods -> decisions -> reviews -> readiness. One connected programme graph.
Product architecture
One generic programme. One evidence spine.
GenRx is designed to keep the development path inspectable from reference-product intelligence through formulation, BE, CMC, quality and ANDA readiness.
GenRx Programme OSEvidence-governed workflow
Reference product
Identity, composition, label, literature, patents and source evidence.
Formulation design
Q1/Q2, excipients, CQAs, design rationale and experimental plan.
Dissolution / IVIVC
Methods, profile comparison, biorelevance and model context.
BE / PBPK / PK
Model assumptions, parameter provenance, risk and qualification.
CMC + scale-up
Process, controls, comparability, transfer and manufacturing evidence.
Quality / QMS
Review state, ownership, CAPA/deviation context and audit continuity.
ANDA readiness
Evidence gaps, decision history and submission-oriented readiness.
RetrievedPredictedComputedMeasuredHuman-reviewed
Product proof
Show what exists. Separate it from what is still being validated.
Investors should be able to distinguish product architecture from roadmap ambition. This page deliberately avoids fabricated traction, revenue, customers, approvals or market share.
Programme OSLIVE
Programme-level development workflow, stage status and decision continuity.
Evidence spineLIVE
Provenance-aware evidence, methods, assumptions and decision context.
Method registryLIVE
Method/model identity, versioning, applicability and use context.
Quality governanceLIVE
Review state, ownership and audit-oriented controls across programme work.
Model-informed workflowsVALIDATING
PBPK/PK/BE-oriented workflows and qualification where scientifically appropriate.
Portfolio intelligenceROADMAP
Cross-programme learning while retaining programme-specific evidence and governance boundaries.
Market logic
Separate the medicines economy from GenRx's software opportunity.
The size of the generic-medicines market is not automatically GenRx TAM. A credible software market model starts from addressable organisations, programme volume and realistic programme / enterprise spend.
Software TAM methodology
Eligible generic-development organisationssourced customer count
× Active development programmesportfolio intensity
× Programme / enterprise spendvalidated contract assumption
= TAM / SAM / SOMwith explicit scope and geography
Investor diligence should show the source list, formula and assumptions behind every TAM/SAM/SOM number. The public page intentionally does not invent a market figure before that methodology is validated.
Go-to-market
Land with one difficult programme. Expand into the organisation.
The wedge is a high-friction programme where evidence continuity and cross-functional decisions are unusually valuable.
One difficult generic programme
Complex oral, modified-release, low-solubility, BE-risk or post-failure rescue programme.
Multiple programmes
Reuse governed workflows, evidence structures and review logic across a portfolio.
Development organisation
Common decision language across formulation, analytical, DMPK/PK, quality and regulatory.
Portfolio intelligence
Governance, integrations, oversight and cross-programme learning at organisation scale.
R&D head · Formulation · Analytical · DMPK / PK · Quality · Regulatory · Portfolio leadership
Business model
Commercial architecture from programme value to enterprise infrastructure.
Packaging and pricing should be validated with customers. The model below defines monetisation vectors without presenting unverified revenue or pricing as current fact.
Per-programme workspace
High-value starting wedge around a defined development programme.
Multi-programme collaboration
Cross-functional workflows, reviews and shared scientific context.
Portfolio governance
Controls, integrations, oversight and organisation-level configuration.
Specialist scientific compute
Usage-based modelling or simulation where a workflow requires it.
Optional services
Onboarding, configuration and validation support without replacing software value.
Defensibility
The moat is the connected operating model - not an AI label.
Value compounds when workflow, evidence, methods and review history remain linked across programmes.
Workflow moatReference product -> formulation -> BE -> CMC -> ANDA.
Evidence moatProvenance, applicability, assumptions and uncertainty.
Programme graphRelationships between attributes, experiments, models and decisions.
Portfolio intelligenceCross-programme learning without losing programme-level governance.
Integration moatScientific models + quality + regulatory evidence + programme operations.
Investor diligence
Make the investment case inspectable, too.
The public narrative should connect to controlled diligence evidence rather than asking investors to accept unsupported claims.
Product architecture
System map, modules, workflow boundaries, release state and implementation evidence.
Scientific validation
QA reports, benchmark cases, evidence-class handling and known limitations.
Security & governance
Authentication, controls, audit approach, data boundaries and enterprise-readiness evidence.
Market model
TAM/SAM/SOM formulas, source list and explicit assumption sheet.
Commercial evidence
Customer discovery, pilot funnel, contracts and usage evidence when available.
Company & finance
Corporate structure, cap table, budget, runway and raise documents under appropriate access control.
Controlled diligence room: sensitive company and financial materials should not be embedded in a public webpage. The dedicated diligence surface explains the package and provides an access-request route.
Open diligence roomCapital to milestones
Capital should map to capability, then to a measurable milestone.
No invented allocation percentages. Once the raise amount and operating plan are fixed, this section can be converted into a precise use-of-funds chart.
Enterprise GenRx platform
↓
Multi-programme production readiness.
Benchmark programmes
↓
Customer-ready evidence packages.
Pilots and partnerships
↓
Repeatable sales motion.
Security + reliability
↓
Procurement readiness.
Validated workflows
↓
Stronger pharma adoption.
NOWProduct foundation
6MCustomer validation target
12MRepeatable programme target
18MEnterprise deployment target
24MPortfolio intelligence target
Invest in the programme layer.
Generic development is still managed across disconnected scientific and regulatory work. GenRx is being built to turn the whole programme into inspectable, governed computational infrastructure - from reference product to ANDA readiness.
Market sources: Association for Accessible Medicines, 2025 U.S. Generic & Biosimilar Medicines Savings Report (90% of prescriptions, 12% of Rx spending, $467B savings in 2024); U.S. FDA, Generic Drugs Program FY2025 Activities Report / GDUFA III performance goals (standard original ANDA review goal of 10 months). These statistics describe industry context, not GenRx revenue or market share.
AAM 2025 Savings Report · FDA FY2025 Generic Drugs Program
AAM 2025 Savings Report · FDA FY2025 Generic Drugs Program